| Description | GLPG-0259 is an inhibitor of mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5). |
| Synonyms | GLPG-0259, GLPG 0259 |
| molecular weight | 460.53 |
| Molecular formula | C24H28N8O2 |
| CAS | 959754-85-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Westhovens R, Keyser FD, Rekalov D, Nasonov EL, Beetens J, Van der Aa A, Wigerinck P, Namour F, Vanhoutte F, Durez P. Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial. Ann Rheum Dis. 2013 May;72(5):741-4. doi: 10.1136/annrheumdis-2012-202221. Epub 2012 Nov 17. PubMed PMID: 23161899. 2. Namour F, Vanhoutte FP, Beetens J, Blockhuys S, De Weer M, Wigerinck P. Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects. Drugs R D. 2012 Sep 1;12(3):141-63. doi: 10.2165/11633120-000000000-00000. PubMed PMID: 22950522; PubMed Central PMCID: PMC3585965. |